We are conducting research aimed at understanding and overcoming diseases that significantly impact the lives of patients and their families, including designated intractable diseases, age-related disorders, and lifestyle-related diseases. With the advancement of genome sequencing technologies, a growing number of human genomic data and pathogenic variants have been identified in recent years. However, the functional mechanisms by which these variants contribute to disease onset remain largely unclear. Our team utilizes CRISPR/Cas9 genome editing technology to develop disease model mice that faithfully recapitulate patient-specific pathological conditions based on individual genomic information. We are particularly focused on neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), as well as renal diseases including Alport syndrome. For phenotypic and pathological analyses of the model mice, we employ the internationally standardized platform of RIKEN BRC. In close collaboration with clinical and pharmaceutical researchers, we also contribute to the development of diagnostic methods, therapeutic strategies, and drug discovery. We aim to advance preclinical research that lays the foundation for precision medicine.